

# Head And Neck Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/HA9E6D26841EN.html>

Date: April 2020

Pages: 2943

Price: US\$ 2,500.00 (Single User License)

ID: HA9E6D26841EN

## Abstracts

Head And Neck Cancer - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H1 2020, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 22, 185, 179, 1, 8, 113, 24 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 10, 11, 1, 21, 4 and 1 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Head And Neck Cancer - Overview

Head And Neck Cancer - Therapeutics Development

Head And Neck Cancer - Therapeutics Assessment

Head And Neck Cancer - Companies Involved in Therapeutics Development

Head And Neck Cancer - Drug Profiles

Head And Neck Cancer - Dormant Projects

Head And Neck Cancer - Discontinued Products

Head And Neck Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Head And Neck Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..10), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..11), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..12), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..13), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..14), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..15), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..16), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..17), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1),  
H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2),  
H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020

## Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Head And Neck Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

2A Pharma AB  
4D Pharma Plc  
4SC AG  
A2 Biotherapeutics Inc  
Aadi Bioscience Inc  
AbbVie Inc  
Abion Inc  
ABL Bio Inc  
Acepodia Biotech Inc  
Adaptimmune Therapeutics Plc  
ADC Therapeutics SA  
Adlai Nortye Biopharma Co Ltd  
Admedus Ltd  
Aduro BioTech Inc  
Advaxis Inc  
Advenchen Laboratories LLC  
Adze Biotechnology Inc  
Affimed GmbH  
Agenus Inc  
Akeso Biopharma Inc  
Alkermes Plc

Alligator Bioscience AB  
Alphamab Oncology  
ALX Oncology Inc  
Ambrx Inc  
amcure GmbH  
Amgen Inc  
AMI Onco Theranostics LLC  
ANP Technologies Inc  
AP Biosciences Inc  
Apexigen Inc  
Apollomics Inc  
Arcus Biosciences Inc  
Argenx SE  
Ascenta Therapeutics Inc  
Ascentage Pharma Group International  
Asclepiumm Taiwan Co Ltd  
AsclepiX Therapeutics Inc  
Astellas Pharma Inc  
Astex Pharmaceuticals Inc  
AstraZeneca Plc  
Atara Biotherapeutics Inc  
Aura Biosciences Inc  
Aurigene Discovery Technologies Ltd  
Avalon GloboCare Corp  
AVEO Oncology Inc  
Aveta Biomics Inc  
Avvinity Therapeutics Ltd  
Bavarian Nordic A/S  
Bayer AG  
BeiGene Ltd  
Bexion Pharmaceuticals LLC  
Bio-Thera Solutions Ltd  
BioAtla LLC  
Biohaven Pharmaceutical Holding Company Ltd  
BioLineRx Ltd  
Biomics Biotechnologies Co Ltd  
Biomimetix JV LLC  
Biomunex Pharmaceuticals  
BioNTech SE



Bioven Group  
BJ Bioscience Inc  
Boehringer Ingelheim International GmbH  
Boryung ViGenCell Inc  
Boston Biomedical Inc  
BrightPath Biotherapeutics Co Ltd  
Bristol-Myers Squibb Co  
Brooklyn ImmunoTherapeutics LLC  
Cancer Therapeutics Laboratories Inc  
Canget BioTekpharma LLC  
CanImGuide Therapeutics AB  
Cantargia AB  
CarboMimetics  
CEL-SCI Corp  
Celldex Therapeutics Inc  
Cellecstar Biosciences Inc  
Cello Therapeutics Inc  
Cellular Biomedicine Group Inc  
Celprogen Inc  
Centurion BioPharma Corp  
Checkmate Pharmaceuticals Inc  
Checkpoint Therapeutics Inc  
Chi Cheung (Shanghai) Biomedical Co Ltd  
China Immunotech Co Ltd  
Corvus Pharmaceuticals Inc  
Cotinga Pharmaceuticals Inc  
CStone Pharmaceuticals Co Ltd  
Cue Biopharma Inc  
Cullinan Oncology LLC  
Curevac AG  
Cyclacel Pharmaceuticals Inc  
Cyteir Therapeutics Inc  
CytImmune Sciences Inc  
Cytocom Inc  
Cytodyn Inc  
CytoMed Therapeutics Pte Ltd  
CytomX Therapeutics Inc  
Daiichi Sankyo Co Ltd  
Debiopharm International SA

DelMar Pharmaceuticals Inc  
DNJ Pharma Inc  
Dragonboat Biopharmaceutical (Shanghai)Co Ltd  
eFFECTOR Therapeutics Inc  
Eisai Co Ltd  
Eli Lilly and Co  
Elicio Therapeutics  
ENB Therapeutics LLC  
EnGeneIC Ltd  
Enzene Biosciences Ltd  
EpicentRx Inc  
Etubics Corp  
Eutilex Co Ltd  
Exelixis Inc  
Exicure Inc  
F. Hoffmann-La Roche Ltd  
Fate Therapeutics Inc  
Fochon Pharma Inc  
Forbius  
Fujifilm Holdings Corp  
G&E Corp  
Galectin Therapeutics Inc  
GEEN Biotechnology Inc  
Geneius Biotechnology Inc  
Genelux Corp  
Genentech Inc  
Genmab AS  
Genocea Biosciences Inc  
GeoVax Labs Inc  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
GLG Pharma SA  
Gliknik Inc  
Glycomantra Inc  
GlycoMira Therapeutics Inc  
Glycotope GmbH  
GT Biopharma Inc  
Guangzhou Double Bioproduct Inc  
Guangzhou Hanghua Bio Pharmaceutical Technology Co

Guangzhou Sinogen Pharmaceutical Co Ltd  
Harbin Gloria Pharmaceuticals Co Ltd  
Harbour BioMed  
Hengenix Biotech Inc  
Hercules Pharmaceuticals BV  
Hookipa Pharma Inc  
Horizon Therapeutics PLC  
Hummingbird Bioscience Pte Ltd  
HylaPharm  
Idera Pharmaceuticals Inc  
ImCheck Therapeutics SAS  
Immatics Biotechnologies GmbH  
ImmuneSensor Therapeutics Inc  
Immunicum AB  
ImmunityBio Inc  
Immunocore Ltd  
Immunomedics Inc  
Immunomic Therapeutics Inc  
Immutep Ltd  
Immvira Co Ltd  
IMV Inc  
Incyte Corp  
Infinity Pharmaceuticals Inc  
Inhibrx Inc  
Innate Pharma SA  
Innovene  
Innovent Biologics Inc  
Inovio Pharmaceuticals Inc  
Intensity Therapeutics Inc  
InteRNA Technologies BV  
Invectys SA  
InxMed Shanghai Co Ltd  
IO Biotech ApS  
Iovance Biotherapeutics Inc  
Ipsen SA  
ISA Pharmaceuticals BV  
iSTAT Therapeutics Inc  
ISU ABXIS Co Ltd  
Jacobio Pharmaceuticals Co Ltd

Jiangsu Hengrui Medicine Co Ltd  
Jiangsu Kanion Pharmaceutical Co Ltd  
Johnson & Johnson  
Jounce Therapeutics Inc  
Juno Therapeutics Inc  
Kiromic BioPharma Inc  
Kitov Pharma Ltd  
Komipharm International Co Ltd  
Konruns Pharmaceutical Co Ltd  
Kuur Therapeutics Ltd  
Kymab Ltd  
Kyowa Kirin Co Ltd  
L.E.A.F. Pharmaceuticals LLC  
Laboratoires Pierre Fabre SA  
LATITUDE Pharmaceuticals Inc  
Leucid Bio Ltd  
LifT BioSciences Ltd  
Lion TCR Pte Ltd  
LipoSeuticals Inc  
Luye Pharma Group Ltd  
Luzitin SA  
Lytix Biopharma AS  
Mabion SA  
MacroGenics Inc  
MAIA Biotechnology Inc  
Mateon Therapeutics Inc  
Maverick Therapeutics Inc  
MaxiVAX SA  
MediciNova Inc  
Medivir AB  
Merck & Co Inc  
Merck KGaA  
Mereo Biopharma Group Plc  
Mersana Therapeutics Inc  
Mirati Therapeutics Inc  
MiRecule Inc  
MiReven Pty Ltd  
Mitsubishi Tanabe Pharma Corp  
Moderna Inc

Modra Pharmaceuticals BV  
Molecular Partners AG  
Molecular Templates Inc  
Moleculin Biotech LLC  
MolMed SpA  
MultiVir Inc  
Nanjing Iaso Biotherapeutics Co Ltd  
NanoCarrier Co Ltd  
NantBioScience Inc  
NantKwest Inc  
Natco Pharma Ltd  
Nektar Therapeutics  
Neonc Technologies Inc  
NeoTX Therapeutics Ltd  
Neumedicines Inc  
NextCure Inc  
NGM Biopharmaceuticals Inc  
Northwest Biotherapeutics Inc  
Novartis AG  
Noxopharm Ltd  
Ocellaris Pharma Inc  
Ona Therapeutics SL  
Oncolmmune Inc  
Oncologie Inc  
Oncology Venture A/S  
Oncolys BioPharma Inc  
Onconova Therapeutics Inc  
Oncorus Inc  
OncoSec Medical Inc  
Oncovir Inc  
Ono Pharmaceutical Co Ltd  
Onxeo SA  
Otsuka Holdings Co Ltd  
Oxford Vacmedix UK Ltd  
PDS Biotechnology Corp  
Pfizer Inc  
Pharma Mar SA  
Philogen SpA  
Phio Pharmaceuticals Corp

Phosplatin Therapeutics LLC  
PIQUR Therapeutics AG  
Plexxikon Inc  
Plus Therapeutics Inc  
PNP Therapeutics Inc  
Polaris Pharmaceuticals Inc  
Potenza Therapeutics Inc  
Precigen Inc  
PRISM Pharma Co Ltd  
Privo Technologies Inc  
Protheragen Inc  
PsiOxus Therapeutics Ltd  
QBiotics Ltd  
Qilu Pharmaceutical Co Ltd  
Qilu Puget Sound Biotherapeutics Corp  
Qrono Inc  
R Pharm  
Rakuten Medical Inc  
RAPT Therapeutics Inc  
RaQualia Pharma Inc  
Refuge Biotechnologies Inc  
Regeneron Pharmaceuticals Inc  
Rimo Therapeutics Inc  
Sanofi  
Sareum Holdings Plc  
Scancell Holdings Plc  
Seattle Genetics Inc  
SEEKYO Therapeutics  
Selecta Biosciences Inc  
Sensei Biotherapeutics Inc  
Shanghai GeneChem Co Ltd  
Shanghai Henlius Biotech Inc  
Shanghai Jing Ze Biotechnology Co Ltd  
Shanghai Junshi Bioscience Co Ltd  
Shanghai Miracogen Inc  
Shattuck Labs Inc  
Shionogi & Co Ltd  
Sichuan Kelun Pharmaceutical Co Ltd  
Sierra Oncology Inc

Sillajen Biotherapeutics  
Sino Biopharmaceutical Ltd  
Sinocelltech Ltd  
Sirnaomics Inc  
Sirona Therapeutics Inc  
SL Bigen Inc  
SMET Pharmaceutical Inc  
Soricimed Biopharma Inc  
Sotio AS  
Spring Bank Pharmaceuticals Inc  
SQZ Biotechnologies Co  
STAT3 Therapeutics Inc  
Stcube Inc  
Stella Pharmaceuticals Pvt Ltd  
StemMed Ltd  
Sumitomo Dainippon Pharma Co Ltd  
SuviCa Inc  
Suzhou Max Bio-tech Co Ltd  
Suzhou Zelgen Biopharmaceutical Co Ltd  
Sveikatal Inc  
Synermore Biologics Co Ltd  
Tactical Therapeutics Inc  
Takis Srl  
Tallikut Pharmaceuticals Inc  
TCRCure Biotech Co Ltd  
Telix Pharmaceuticals Ltd  
Tempest Therapeutics Inc  
Tessa Therapeutics Pte Ltd  
Theralase Technologies Inc  
Theravectys SA  
Tolero Pharmaceuticals Inc  
Torque Therapeutics Inc  
TOT Biopharm Co Ltd  
Transgene SA  
Trovagene Inc  
Turning Point Therapeutics Inc  
Turnstone Biologics Inc  
Tvardi Therapeutics Inc  
Tyme Technologies Inc

UbiVac LLC  
Vaccibody AS  
Vaccinex Inc  
VasGene Therapeutics Inc  
Vault Pharma Inc  
VCN Biosciences SL  
Veana Therapeutics LLC  
Vectorite Biomedical Inc  
Venus Remedies Ltd  
Verastem Inc  
Viracta Therapeutics Inc  
Viralytics Pty Ltd  
Virion Therapeutics LLC  
Voronoi  
Vyriad Inc  
Wayshine Biopharma Inc  
Wuhan Binhui Biotechnology Co Ltd  
Xbrane Biopharma AB  
Xencor Inc  
Xiangxue Life Sciences  
XuanZhu Pharma Co Ltd  
Xynomic Pharmaceuticals Holdings Inc  
Zhejiang Yangshengtang Biotech Co Ltd  
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd  
Zymeworks Inc



## I would like to order

Product name: Head And Neck Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/HA9E6D26841EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HA9E6D26841EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970